Immunogenicity shown in Prevenar 13 studies

According to RTT News, in a Phase III safety and immunogenicity study, Prevenar 13 showed that the vaccine was immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar. This proved that there was a prevention of pneumonia and Streptococcus pneumoniae in children under five years old. Read the whole article here.

Share this article with your social network, just click below to share now!

Share |